| D60 | Ethical issues surrounding HIV testing within the context of the HIV Treat All strategy implementation: the case of three hospitals in Cameroon | E-poster | Positive health, dignity, psychological well-being, and mental health |
| D70 | Ethical and practical considerations for scaling up cell and gene therapy towards an HIV-1 cure | E-poster | HIV cure representations and perceptions |
| C2 | Estimating the population size of children of female sex workers: An analysis of ten countries across sub-Saharan Africa | E-poster | Epidemiology of HIV in paediatric and adolescent populations |
| C14 | Estimating the impact of HIV on cervical cancer elimination: a comparative modelling analysis in South Africa | E-poster | Modelling the HIV epidemic |
| D53 | Estimating proportions of hidden populations under respondent-driven sampling | E-poster | Strengthening social and behavioural data collection and analysis |
| B40 | Estimating minimum adherence required for plasma HIV-1 RNA viral load suppression among people who use unregulated drugs in Vancouver, Canada | E-poster | Adherence measurement |
| C19 | Estimates of undiagnosed children living with HIV in Eswatini, Malawi, Tanzania and Zambia using the Population HIV Incidence Assessments (PHIA) | E-poster | Measuring the epidemic through population-based surveys, including the undiagnosed fraction |
| C27 | Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP | On-demand oral abstract session | PrEP |
| C5 | Estimated HIV prevalence and incidence among people who inject drugs in Thessaloniki, Greece (ALEXANDROS program) | E-poster | Epidemiology of HIV in people who use drugs |
| D41 | Estimated cost-based generic prices for key ARVs and effect of COVID-19 on manufacturing costs | E-poster | Impact of COVID-19 on HIV funding |